UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 74

Sortiert nach

Consensus clustering methodology to improve molecular stratification of non-small cell lung cancer

Scientific reports, 2023-05, Vol.13 (1), p.7759-7759, Article 7759

2023

Volltextzugriff (PDF)

Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016

Annals of oncology, 2018-12, Vol.29 (12), p.2288-2295

2018

Volltextzugriff (PDF)

Addressing the unmet need in lung cancer: The potential of immuno-oncology

Cancer treatment reviews, 2015-06, Vol.41 (6), p.465-475

2015

Volltextzugriff (PDF)

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis

Annals of oncology, 2011-10, Vol.22 (10), p.2277-2285

2011

Volltextzugriff (PDF)

Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2002-11, Vol.20 (21), p.4285-4291

2002

Volltextzugriff (PDF)

Prognostic and predictive factors in a randomized phase III trial comparing cisplatin–pemetrexed versus cisplatin–gemcitabine in advanced non-small-cell lung cancer

Annals of oncology, 2010-03, Vol.21 (3), p.556-561

2010

Volltextzugriff (PDF)

Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials

Lung cancer (Amsterdam, Netherlands), 2014-09, Vol.85 (3), p.408-414

2014

Volltextzugriff (PDF)

Long term control of luteinized thecoma with sclerosing peritonitis with leuprorelin and tamoxifen treatment

Gynecologic oncology reports, 2019-05, Vol.28, p.44-46

2019

Volltextzugriff (PDF)

Meta-Analysis Examining Impact of Age on Pemetrexed (pem) Efficacy for the Treatment of Advanced Nonsquamous (NS) Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S43-S43

2014

Volltextzugriff (PDF)

3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy

European journal of cancer (1990), 2015-09, Vol.51, p.S621-S621

2015

Volltextzugriff (PDF)

Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a b in solid cancer

Oncogene, 2011-06, Vol.30 (25), p.2888-2899

2011

Volltextzugriff (PDF)

Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer

Annals of oncology, 2013-01, Vol.24 (1), p.59-66

2013

Volltextzugriff (PDF)

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

Annals of oncology, 2006-12, Vol.17 (12), p.1818-1825

2006

Volltextzugriff (PDF)

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer

Annals of oncology, 2015-03, Vol.26 (3), p.497-504

2015

Volltextzugriff (PDF)

Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET

Annals of oncology, 2015-10, Vol.26 (10), p.2007-2009

2015

Volltextzugriff (PDF)

Challenging the platinum combinations in the chemotherapy of NSCLC

Lung cancer (Amsterdam, Netherlands), 2002-12, Vol.38, p.21-28

2002

Volltextzugriff (PDF)

1368P TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) – Exploration of tumor genetics associated with prolonged benefit

Annals of oncology, 2022-09, Vol.33, p.S1167

2022

Volltextzugriff (PDF)

Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer

Annals of oncology, 2004-01, Vol.15 (1), p.28-32

2004

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Pathway in Non-Small-Cell Lung Cancer

Annals of oncology, 2012-10, Vol.23, p.xi12

2012

Volltextzugriff (PDF)

Phase ii study of mytomicin-c plus uft/lv in patients with metastatic colorectal cancer refractory to standard chemotherapy. subgroup analysis of predictive variables in discriminating early progressors

Annals of oncology, 2016-09, Vol.27, p.iv53

2016

Volltextzugriff (PDF)

A systematic review of the safety profile of bolus, continuous infusion of 5-fu and capecitabine in combination with oxaliplatin in the treatment of colorectal cancer patients

Annals of oncology, 2016-09, Vol.27, p.iv50

2016

Volltextzugriff (PDF)

Association between levels of hormones implied in steroid biosynthesis pathway and activity of abiraterone acetate (AA) in patients (pts) with metastatic castration- resistant prostate cancer (mCRPC): an exploratory analysis

Annals of oncology, 2015-10, Vol.26, p.vi61

2015

Volltextzugriff (PDF)

Prospective generation of PDTX (patient derived tumor xenografts) and molecular profiling of NSCLC (non small cell lung cancer)

Annals of oncology, 2017-10, Vol.28, p.vi58-vi58

2017

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(72)

Publikationsform

Artikel
(74)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(35)
Science & Technology
(32)
Life Sciences & Biomedicine
(31)
Oncology
(29)
Lung Neoplasms - Drug Therapy
(24)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(23)
Biological And Medical Sciences
(19)
Medical Sciences
(19)
Female
(17)
Male
(17)
Middle Aged
(16)
Aged
(14)
Antineoplastic Agents
(14)
Pharmacology. Drug Treatments
(14)
Pneumology
(13)
Tumors Of The Respiratory System And Mediastinum
(13)
Adult
(12)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(12)
Cisplatin - Administration & Dosage
(10)
Lung Neoplasms - Pathology
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Consensus clustering methodology to improve molecular stratification of non-small cell lung cancer

Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016

Addressing the unmet need in lung cancer: The potential of immuno-oncology

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis

Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer

Prognostic and predictive factors in a randomized phase III trial comparing cisplatin–pemetrexed versus cisplatin–gemcitabine in advanced non-small-cell lung cancer

Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials

Long term control of luteinized thecoma with sclerosing peritonitis with leuprorelin and tamoxifen treatment

Meta-Analysis Examining Impact of Age on Pemetrexed (pem) Efficacy for the Treatment of Advanced Nonsquamous (NS) Non-Small Cell Lung Cancer (NSCLC)

3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy

Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a b in solid cancer

Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer

Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET

Challenging the platinum combinations in the chemotherapy of NSCLC

1368P TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) – Exploration of tumor genetics associated with prolonged benefit

Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer

Epidermal Growth Factor Receptor Pathway in Non-Small-Cell Lung Cancer

Phase ii study of mytomicin-c plus uft/lv in patients with metastatic colorectal cancer refractory to standard chemotherapy. subgroup analysis of predictive variables in discriminating early progressors

A systematic review of the safety profile of bolus, continuous infusion of 5-fu and capecitabine in combination with oxaliplatin in the treatment of colorectal cancer patients

Association between levels of hormones implied in steroid biosynthesis pathway and activity of abiraterone acetate (AA) in patients (pts) with metastatic castration- resistant prostate cancer (mCRPC): an exploratory analysis

Prospective generation of PDTX (patient derived tumor xenografts) and molecular profiling of NSCLC (non small cell lung cancer)

Suchergebnisse filtern